Treatment of T-cell non-Hodgkin's lymphoma

Current Treatment Options in Oncology
Andrew M Evens, Ronald B Gartenhaus

Abstract

T-cell non-Hodgkin's lymphoma (NHL) represents approximately 10% to 15% of all lymphomas in Western countries. Patients with T-cell NHL are often treated similarly to patients with intermediate grade B-cell NHL, although many reports have demonstrated lower overall survival rates in patients with T-cell NHL compared to patients with B-cell NHL. Updated classifications have recognized specific clinical and pathologic T-cell entities, such as peripheral T-cell lymphoma, not otherwise characterized, angioimmunoblastic lymphoma, systemic anaplastic T-cell lymphoma, adult T-cell leukemia/lymphoma, subcutaneous panniculitis-like T-cell lymphoma, hepatosplenic T-cell lymphoma, extranodal natural killer (NK)/T-cell lymphoma nasal type, and enteropathy-type intestinal T-cell lymphoma. Furthermore, these distinct T-cell NHL subtypes often warrant individualized diagnostic and therapeutic strategies, such as the associated cytophagic histiocytic panniculitis and hemophagocytic syndrome with subcutaneous panniculitis-like T-cell lymphoma, the chromosomal translocation t(2;5), leading to the nucleophosmin anaplastic lymphoma kinase fusion protein, viral pathogenesis of Epstein-Barr virus, human T-cell lymphotropic virus type-1 associated wi...Continue Reading

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M AnsellJ P Colgan
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M M CheungR K Ngan
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J O Armitage, D D Weisenburger
Feb 5, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniS Tura
Aug 11, 1999·Seminars in Immunology·A C HaydayE S Hoffman
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G E KimB S Kim
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GaleD H Wright
Aug 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R S SiegelT M Kuzel
May 1, 2001·British Journal of Haematology·S SallahN P Nguyen
Sep 5, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J RodriguezI F Khouri
Oct 12, 2001·Annals of the New York Academy of Sciences·R Kurzrock
Nov 8, 2001·Leukemia & Lymphoma·W K HofmannH P Koeffler
Dec 4, 2001·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·G E KimK M Kim
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T RüdigerUNKNOWN Non-Hodgkin's Lymphoma Classification Project
Mar 23, 2002·Leukemia & Lymphoma·Rakhshandra TalpurMadeleine Duvic
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·G QuintiniG Mariani
Jun 13, 2002·British Journal of Haematology·Emilio IannittoMonica Leone
Jul 4, 2002·FEBS Letters·G Chris FillmoreMegan S Lim
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffery L Kutok, Jon C Aster
Nov 29, 2002·Frontiers in Bioscience : a Journal and Virtual Library·Andrew M Evens, Ronald B Gartenhaus

❮ Previous
Next ❯

Citations

Aug 30, 2008·Journal of Clinical Pathology·C AgostinelliS A Pileri
Jun 2, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Mala SharmaHarit Desai
Aug 7, 2010·Current Hematologic Malignancy Reports·Pier Paolo PiccalugaStefano A Pileri
Apr 29, 2010·Current Hematologic Malignancy Reports·Francesco d'AmoreThomas Relander
Apr 22, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Antonio RuedaAngeles Medina-Pérez
Aug 2, 2011·Expert Review of Hematology·Pier Paolo PiccalugaUNKNOWN European T‑cell Lymphoma Study Group
Nov 25, 2006·Hematology·John P Greer
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie VoseUNKNOWN International T-Cell Lymphoma Project
Apr 21, 2011·Leukemia & Lymphoma·Pier Luigi ZinzaniMichele Baccarani
Jan 30, 2020·Wiener medizinische Wochenschrift·Ivanka Temelkova, Georgi Tchernev
Feb 28, 2007·Leukemia & Lymphoma·Myron S CzuczmanUNKNOWN Cancer and Leukemia Group B
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip WentStefano A Pileri
Mar 28, 2009·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tadeusz RobakPawel Robak
Nov 6, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniM Baccarani
Aug 17, 2011·Seminars in Diagnostic Pathology·Stefano A PileriPier Paolo Piccaluga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis